INNV-21. IN NEWLY-DIAGNOSED GLIOBLASTOMA, FRAILTY/SARCOPENIA PREDICTS 30D MORBIDITY & 30D, 90D, AND OVERALL MORTALITY AS ACCURATELY AS CURRENT STANDARDS

INTRODUCTION: Identification of novel prognostic biomarkers for glioblastoma (GBM) could stratify patients between aggressive or palliative treatments. Frailty, as measured by sarcopenia (lack of muscle mass), has been proven to predict survival in cancers. We evaluate whether the frailty/sarcopenia...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neuro Oncol
Main Authors: Zakaria, Hesham, Chandra, Ankush, Macki, Mohamed, Robin, Adam, Walbert, Tobias, Chang, Victor, Kalkanis, Steven, Lee, Ian
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Innovations in Patient Care
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847745/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.564
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki